

[99] EYEYON MEDICAL

Nahum Ferera¹, ¹ Golda Meir 5

- **Investment** **Rational**
EyeYon Medical provides innovative, patent protected solutions that proved feasibility for corneal healing, including corneal edema. More than 13 million people are waiting for cornea from a human donor, as there is a great global shortage of corneas. EyeYon's technology is the answer for that need. EyeYon Medical partners are leading VC's such as Rimonci (China), TriVentures, Pontifax.

Business Strategy

EyeYon's products address an unmet clinical need. EndoArt® is a revolutionary product, expected to change the ophthalmology market, eliminating the need for human source cornea transplant.

Hyper-CL™ generates first revenues from pilot sales in Europe and Asia. EyeYon is expending its Hyper-CL™ market both geographically and clinically, as the Hyper CL™ is a drug depo tool, it can be used to treat wide corneal pathologies.

Core Technology

What is the technology, its uniqueness and its value proposition

EndoArt® - an artificial endothelial layer that cures corneal edema using a silicon implant attached to the corneal surface. The implantation of the EndoArt® prevents fluids transfer into the cornea and avoid the creation of edema.

Hyper-CL™ - a therapeutic contact lens with a unique design that creates a reservoir above the cornea. This reservoir can store eye-drops applied to the eye surface for increased contact time and effectiveness.

- **Product Profile/Pipeline**

EndoArt® - In clinical stage with initial promising human results. First in Men trial expected to end by mid-2019, and CE approval expected by end 2020. Potential market estimation of > \$8B.

Hyper-CL™ - CE and FDA cleared, in commercialization stage. Expanding market with new treatment indications: infections, inflammation, dry eye, etc.

- **What's Next?**

2018-2019 - EndoArt® FIM trial and CE submission. 2018 - Hyper CL™ clinical trials for corneal edema and other indications to broaden the market. CFDA Clearance in expected by end of 2019. 2019 - Next financial round. EyeYon is also looking to collaborate with a big strategic partner.